Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058531 | 0.94 | BTK (0.73) | BTK | |
| SCHEMBL3064210 | 0.90 | BTK (0.64) | BTK | |
| SCHEMBL3208952 | 0.90 | BTK (0.87) | BTK | |
| SCHEMBL13154112 | 0.89 | BTK (0.72) | BTK | |
| SCHEMBL3063242 | 0.87 | BTK (0.77) | BTK | |
| SCHEMBL3208530 | 0.87 | BTK (0.81) | BTK | |
| SCHEMBL707851 | 0.86 | BTK (0.80) | BTK | |
| SCHEMBL3210174 | 0.85 | BTK (0.86) | BTK | |
| SCHEMBL3208593 | 0.84 | BTK (0.78) | BTK | |
| SCHEMBL3199749 | 0.83 | BTK (1.00) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | claimed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | claimed |
| EP-2421854-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | disclosed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | disclosed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.